Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

Coloplast reported a second-quarter loss versus a profit a year earlier, citing a hefty impairment loss tied to Kerecis despite higher revenue. The update is negative for earnings quality and near-term profitability, though the article also notes the company reaffirmed its fiscal 2026 outlook.

Analysis

Coloplast reported a second-quarter loss versus a profit a year earlier, citing a hefty impairment loss tied to Kerecis despite higher revenue. The update is negative for earnings quality and near-term profitability, though the article also notes the company reaffirmed its fiscal 2026 outlook.